Tag: BIO TECH

Arcturus Therapeutics (Nasdaq: ARCT) has been granted orphan medicinal product designation by the European Commission (EC) for ARCT-032 in the treatment of Cystic Fibrosis (CF)…. [Read More]

Neurodegenerative disease company, NeuroSense Therapeutics (Nasdaq: NRSN) has reported additional positive data from its six-month double-blind Phase 2b PARADIGM trial of PrimeC for the treatment… [Read More]

Cybin Inc. (NYSE American: CYBN) has reported its unaudited financial results for its third quarter ended December 31, 2023 and highlighted positive Phase 2 topline… [Read More]

Aytu Biopharma (Nasdaq: AYTU) has announced its financial and operational results for the fiscal 2024 second quarter. The company’s ADHD Portfolio (Adzenys XR-ODT® and Cotempla… [Read More]

Adverum Biotechnologies (Nasdaq: ADVM) has reported positive preliminary safety and efficacy data from a Phase 2 trial in patients with wet age-related macular degeneration (AMD)… [Read More]

 Tonix Pharmaceuticals (Nasdaq: TNXP) is offering new hope to the 6 – 12 million Americans living with fibromyalgia with a potential new frontline treatment that… [Read More]

Shares in rapid test solutions company, Intelligent Bio Solutions (Nasdaq: INBS), surged nearly 240% in intraday trading on Friday after the company reported its financial… [Read More]

 AIM ImmunoTech (NYSE American: AIM) has reported positive topline results from a Phase 2 study evaluating the efficacy and safety of Ampligen® as a potential… [Read More]

Biodexa Pharmaceuticals (Nasdaq: BDRX) has provided survival updates from its clinical study of MTX110 in patients with recurrent glioblastoma (“rGBM”). Currently, no standard of care… [Read More]

Surgical robotics company, Microbot Medical (Nasdaq: MBOT) has taken an important step closer to initiating a pivotal human clinical trial in the United States with… [Read More]